Why most LPA/S1P-pathway drugs failed outside autoimmunity: a pharmacological post-mortem and the next-generation agenda

Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) signal through eleven rhodopsin-class GPCRs: six LPA receptors (LPA1–6) and five S1P receptors (S1P1–5). The axis transformed autoimmunity (fingolimod, siponimod, ozanimod, ponesimod, etrasimod). Yet mechanism-based programs repeatedly failed or stalled in oncology and fibrosis. The LPA1 antagonist BMS-986020 showed phase 2 efficacy in idiopathic pulmonary fibrosis (IPF) but was withdrawn for hepatobiliary toxicity; the autotaxin inhibitor ziritaxestat failed two phase 3 trials; the anti-S1P antibody sonepcizumab missed its progression-free-survival endpoint in metastatic renal cell carcinoma; and the LPA1 antagonist fipaxalparant missed its primary and all 13 secondary endpoints in phase 2 IPF (company-reported). In October 2026, company-reported phase 3 ALOFT-IPF topline became the first late-phase positive result on this axis: the second-generation LPA1 antagonist admilparant met its primary endpoint at 60 mg twice daily but not at 120 mg, with effect sizes undisclosed. The clinical record contradicts three assumptions carried over from immunology’s successes: that receptor occupancy predicts clinical effect, that a single node can control a multi-source ligand system, and that rodent findings extrapolate to humans. In stromal, epithelial and tumor cells, unlike lymphocytes, desensitization kinetics blunt the ‘functional antagonism’ paradigm; autotaxin-independent LPA sources and the large circulating S1P sink limit what single-node intervention can achieve; and species differences in bile-acid transporter inhibition and cardiovascular pharmacology are substantial. Next-generation programs should be designed around one quantitative question: which flux node dominates the disease compartment, and at what signaling tone? The source–pool–sink framework provides the measurements needed to answer it.

Authors

Institutions

Publication Details

Published
2026-11-12
DOI
https://doi.org/10.22541/authorea.15012125/v1
Primary Topic
Sphingolipid Metabolism and Signaling
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Why most LPA/S1P-pathway drugs failed outside autoimmunity: a pharmacological post-mortem and the next-generation agenda

Xiaoying Wuᵇ, Zhengyi Wangᵃ
Sphingolipid Metabolism and Signaling
preprint

Why most LPA/S1P-pathway drugs failed outside autoimmunity: a pharmacological post-mortem and the next-generation agenda

Xiaoying Wuᵇ, Zhengyi Wangᵃ
preprint en

Abstract

Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) signal through eleven rhodopsin-class GPCRs: six LPA receptors (LPA1–6) and five S1P receptors (S1P1–5). The axis transformed autoimmunity (fingolimod, siponimod, ozanimod, ponesimod, etrasimod). Yet mechanism-based programs repeatedly failed or stalled in oncology and fibrosis. The LPA1 antagonist BMS-986020 showed phase 2 efficacy in idiopathic pulmonary fibrosis (IPF) but was withdrawn for hepatobiliary toxicity; the autotaxin inhibitor ziritaxestat failed two phase 3 trials; the anti-S1P antibody sonepcizumab missed its progression-free-survival endpoint in metastatic renal cell carcinoma; and the LPA1 antagonist fipaxalparant missed its primary and all 13 secondary endpoints in phase 2 IPF (company-reported). In October 2026, company-reported phase 3 ALOFT-IPF topline became the first late-phase positive result on this axis: the second-generation LPA1 antagonist admilparant met its primary endpoint at 60 mg twice daily but not at 120 mg, with effect sizes undisclosed. The clinical record contradicts three assumptions carried over from immunology’s successes: that receptor occupancy predicts clinical effect, that a single node can control a multi-source ligand system, and that rodent findings extrapolate to humans. In stromal, epithelial and tumor cells, unlike lymphocytes, desensitization kinetics blunt the ‘functional antagonism’ paradigm; autotaxin-independent LPA sources and the large circulating S1P sink limit what single-node intervention can achieve; and species differences in bile-acid transporter inhibition and cardiovascular pharmacology are substantial. Next-generation programs should be designed around one quantitative question: which flux node dominates the disease compartment, and at what signaling tone? The source–pool–sink framework provides the measurements needed to answer it.

University of Electronic Science and Technology of China (CN), Chengdu Second People's Hospital (CN)
Sphingolipid Metabolism and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon